

# C-61

## Clinical Utility of a Molecular Cancer Classifier for Primary Site Identification in Neuroendocrine Tumors

**Brianne A. Voros<sup>1</sup>**; Cody Gulizo<sup>2</sup>; J. Philip Boudreaux<sup>1</sup>; Ramcharan Thiagarajan<sup>1</sup>; Robert A. Ramirez<sup>3</sup>; Eugene A. Woltering<sup>1</sup>

<sup>1</sup>Louisiana State University Health Sciences Center;

<sup>2</sup>The University of New Orleans; <sup>3</sup>Ochsner Clinic Foundation

**BACKGROUND:** Neuroendocrine tumors (NETs) vary significantly in their clinical presentation and biological behavior based on primary site of origin. In patients with metastatic NETs, identification of the primary tumor site is essential for clinical management and to determine prognosis. We sought to determine the clinical utility of a 92-gene panel assay in patients with metastatic NET of unknown primary site.

**METHODS:** In this study, we reviewed patients with a metastatic NET of unknown primary site who were evaluated with a 92-gene panel assay as part of routine care. Demographics, pathology, and treatment data were collected. Based on the assay prediction, patients were further evaluated with surgical exploration, endoscopic procedures, and/or imaging. Predictions were classified as “correct” if confirmed on further evaluation or “incorrect” if the primary site was identified in a different location or could not be found where predicted.

**RESULTS:** Results of the 92-gene panel assay were reported in 150 patients. The assay prediction of GI carcinoid was correct on further evaluation in 88% of patients. The assay was correct in less than half of patients when islet cell carcinoid (47%) and lung carcinoid (40%) were predicted. In 50 patients (33%) with incorrect assay predictions, the primary tumor was identified in a different location on surgical exploration (14%), endoscopic procedure (6%), or imaging (4%). The remaining 38 patients (76%) underwent extensive evaluation in attempts to identify their primary tumor (Table 1).

**CONCLUSION:** In this study, we determined that a 92-gene panel assay may be useful in patients with metastatic NETs of unknown primary site. A prediction of GI carcinoid may provide guidance for clinicians, especially surgeons, in identifying the primary tumor while predictions of islet cell and lung carcinoid require more extensive evaluation.

**Table 1:**

**Results by Subtype Predicted by a 92-gene Panel Assay (N=150)**

<b>Assay Prediction</b>	<b>N</b>	<b>Correct, N (%)</b>	<b>Incorrect, N (%)</b>
GI Carcinoid	85	75 (88)	10 (12)
Islet Cell	32	15 (47)	17 (53)
Lung Carcinoid	15	6 (40)	9 (60)
Other NET	9	3 (33)	6 (67)
Other Cancer	9	1 (11)	8 (89)

**Abbreviations: NET, neuroendocrine tumor**